{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:52:33Z","timestamp":1787727153697,"version":"build-2784847793"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study aims to assess risk of venous thromboembolism (VTE) in patients with Cushing's disease (CD) compared to acromegaly and non-functioning pituitary adenomas (NFPAs) and to investigate the timing and risk factors for VTE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>This is a retrospective, observational cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients diagnosed with acromegaly, NFPA, or CD across 3 UK centres between 2010 and 2021 were included. \u03c7\u00b2 and Cox regression were performed to compare VTE cumulative incidence and examine associations with clinical factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 827 patients (107 CD, 502 NFPA, 218 acromegaly), the cumulative incidence of VTE was 11.2% in CD, 0.4% in NFPA, and 2.7% in acromegaly. Follow-up time was similar across diagnostic groups (median \u223c13.3-13.5 years, P = .41), allowing valid comparison of VTE incidence and Cox regression modelling. Patients with CD had significantly higher VTE risk compared to those with NFPA (odds ratio [OR] 21.05, P &amp;lt; .001) and acromegaly (OR 4.48, P = .002). Cox regression showed that CD diagnosis (hazard ratio [HR] 46.87, P &amp;lt; .001) and history of diabetes or impaired glucose tolerance (HR 3.48, P = .008) were significantly associated with VTE. In patients with CD, there were 12 VTEs recorded, with most (8\/12) occurring within 1 year of CD diagnosis. Notably, 4 VTEs occurred within 45 days post-transsphenoidal surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with CD exhibit a significantly elevated risk of VTE compared to those with acromegaly or NFPA, with diabetes mellitus independently associated with this risk. In CD, VTEs were more frequently diagnosed around the time of diagnosis and during the peri-operative period.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf139","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T14:12:05Z","timestamp":1751551925000},"page":"270-277","source":"Crossref","is-referenced-by-count":3,"title":["Venous thromboembolism in patients with pituitary adenoma: UK multicentre cohort study"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1817-4597","authenticated-orcid":false,"given":"Kristina","family":"Isand","sequence":"first","affiliation":[{"name":"Institute of Biomedicine and Translational Medicine, University of Tartu, U\u0308likooli 18, Tartu 50090 ,","place":["Estonia"]},{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals, Oxford OX37LE ,","place":["United Kingdom"]},{"name":"Department of Endocrinology, North Estonia Medical Centre , Tallinn 13419 ,","place":["Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-5735","authenticated-orcid":false,"given":"Riccardo","family":"Pofi","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital , Oxford OX37LE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Haermson","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals, Oxford OX37LE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Vergis","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners , Birmingham B15 2TT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harishanthi","family":"Mahendran","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners , Birmingham B15 2TT ,","place":["United Kingdom"]},{"name":"Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, IBR Tower, Level 2, Birmingham B15 2TT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ayuk","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners , Birmingham B15 2TT ,","place":["United Kingdom"]},{"name":"Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust , Birmingham B15 2TH ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wass","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals, Oxford OX37LE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Yajnik","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals Bristol and Weston NHS Foundation Trust , Bristol BS1 3NU ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals Bristol and Weston NHS Foundation Trust , Bristol BS1 3NU ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-0643","authenticated-orcid":false,"given":"Niki","family":"Karavitaki","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners , Birmingham B15 2TT ,","place":["United Kingdom"]},{"name":"Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, IBR Tower, Level 2, Birmingham B15 2TT ,","place":["United Kingdom"]},{"name":"Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust , Birmingham B15 2TH ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Pal","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals, Oxford OX37LE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"2","key":"2025081217164809500_lvaf139-B1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00000658-197708000-00006","article-title":"Epidemiology of venous thromboembolism","volume":"186","author":"Coon","year":"1977","journal-title":"Ann Surg"},{"issue":"1","key":"2025081217164809500_lvaf139-B2","first-page":"125","article-title":"Immediate complications of adrenal surgery","volume":"172","author":"Pezzulich","year":"1970","journal-title":"Ann Surg"},{"issue":"1-6","key":"2025081217164809500_lvaf139-B3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.0954-6820.1976.tb06697.x","article-title":"Thromboembolic complications, heparin treatment in increase in coagulation factors in Cushing's syndrome","volume":"199","author":"Sj\u00f6berg","year":"1976","journal-title":"Acta Med Scand"},{"issue":"6","key":"2025081217164809500_lvaf139-B4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1210\/endrev\/bnad016","article-title":"Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad?","volume":"44","author":"Pofi","year":"2023","journal-title":"Endocr Rev."},{"key":"2025081217164809500_lvaf139-B5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3389\/fendo.2018.00805","article-title":"Hypercoagulability and risk of venous thromboembolic events in endogenous Cushing's syndrome: a systematic meta-analysis","volume":"9","author":"Wagner","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2025081217164809500_lvaf139-B6","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1210\/jc.2011-1661","article-title":"Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study","volume":"96","author":"Stuijver","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025081217164809500_lvaf139-B7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4183\/aeb.2020.123","article-title":"Cushing's syndrome, a risk factor for venous thromboembolism, is a candidate for guidelines","volume":"16","author":"Kora\u0107evi\u0107","year":"2020","journal-title":"Acta Endocrinologica (Bucharest)"},{"issue":"5","key":"2025081217164809500_lvaf139-B8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/EJE-10-0583","article-title":"Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery","volume":"163","author":"Manetti","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2025081217164809500_lvaf139-B9","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1210\/jcem.87.8.8703","article-title":"Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome","volume":"87","author":"Boscaro","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025081217164809500_lvaf139-B10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF03346905","article-title":"Recurrent thromboembolism as a hallmark of Cushing's syndrome","volume":"20","author":"La Brocca","year":"1997","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2025081217164809500_lvaf139-B11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/ejendo\/lvad176","article-title":"High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgery","volume":"190","author":"Isand","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025081217164809500_lvaf139-B12","doi-asserted-by":"publisher","first-page":"bvz033","DOI":"10.1210\/jendso\/bvz033","article-title":"Hypercoagulability in Cushing syndrome, prevalence of thrombotic events: a large, single-center, retrospective study","volume":"4","author":"Suarez","year":"2020","journal-title":"J Endocr Soc."},{"issue":"8","key":"2025081217164809500_lvaf139-B13","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1210\/jc.2009-0290","article-title":"Hypercoagulable state in Cushing's syndrome: a systematic review","volume":"94","author":"Van Zaane","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2025081217164809500_lvaf139-B14","first-page":"238","volume-title":"Endocrine Abstracts","author":"Isand","year":"2022"},{"issue":"1","key":"2025081217164809500_lvaf139-B15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13023-022-02320-x","article-title":"Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN)","volume":"17","author":"van Haalen","year":"2022","journal-title":"Orphanet J Rare Dis."},{"issue":"4","key":"2025081217164809500_lvaf139-B16","doi-asserted-by":"publisher","first-page":"M11","DOI":"10.1530\/EJE-15-0198","article-title":"Adverse effects of glucocorticoids: coagulopathy","volume":"173","author":"Coelho","year":"2015","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2025081217164809500_lvaf139-B17","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1210\/jc.2011-2753","article-title":"The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy","volume":"97","author":"van der Pas","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2025081217164809500_lvaf139-B18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1365-2125.2010.03812.x","article-title":"von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing's disease","volume":"71","author":"Giraldi","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2025081217164809500_lvaf139-B19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1530\/EJE-19-0817","article-title":"Prothrombotic fibrin network characteristics in patients with acromegaly: a novel mechanism for vascular complications","volume":"182","author":"Kyriakakis","year":"2020","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2025081217164809500_lvaf139-B20","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1210\/clinem\/dgz136","article-title":"Time to diagnosis in Cushing's syndrome: a meta-analysis based on 5367 patients","volume":"105","author":"Rubinstein","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025081217164809500_lvaf139-B21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito","year":"2020","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2025081217164809500_lvaf139-B22","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1093\/ejendo\/lvac012","article-title":"Is it a risk factor, a predictor, or even both? The multiple faces of multivariable regression analysis","volume":"188","author":"Groenwold","year":"2023","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2025081217164809500_lvaf139-B23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression","volume":"165","author":"Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"5","key":"2025081217164809500_lvaf139-B24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"JCO"},{"issue":"3","key":"2025081217164809500_lvaf139-B25","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jvsv.2021.08.019","article-title":"Meta-analysis and systematic review of randomized controlled trials assessing the role of thromboprophylaxis after vascular surgery","volume":"10","author":"Haykal","year":"2022","journal-title":"J Vasc Surg Venous Lymphat Disord."},{"key":"2025081217164809500_lvaf139-B26","author":"Fleseriu"},{"issue":"6","key":"2025081217164809500_lvaf139-B27","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing's syndrome: a cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2025081217164809500_lvaf139-B28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11102-024-01482-0","article-title":"Can we predict the risk of venous thromboembolism in patients with Cushing's syndrome: a nationwide cohort analysis","volume":"28","author":"Rudman","year":"2024","journal-title":"Pituitary"},{"issue":"5","key":"2025081217164809500_lvaf139-B29","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EJE-20-1309","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing's syndrome: a practical approach","volume":"184","author":"Varlamov","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2025081217164809500_lvaf139-B30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/ejendo\/lvad041","article-title":"Low-grade inflammation during the glucocorticoid withdrawal phase in patients with Cushing's syndrome","volume":"188","author":"Vogel","year":"2023","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2025081217164809500_lvaf139-B31","doi-asserted-by":"publisher","first-page":"R17","DOI":"10.1093\/ejendo\/lvaf017","article-title":"Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement","volume":"192","author":"Isand","year":"2025","journal-title":"Eur J Endocrinol."},{"key":"2025081217164809500_lvaf139-B32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.wneu.2024.08.090","article-title":"Venous thromboembolism and prevention strategies in patients with Cushing's disease: a systematic review","volume":"191","author":"White","year":"2024","journal-title":"World Neurosurg"},{"issue":"4","key":"2025081217164809500_lvaf139-B33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11102-014-0600-y","article-title":"Perioperative thromboprophylaxis in Cushing's disease: what we did and what we are doing?","volume":"18","author":"Barbot","year":"2015","journal-title":"Pituitary"},{"key":"2025081217164809500_lvaf139-B34","doi-asserted-by":"publisher","first-page":"101371","DOI":"10.1016\/j.inat.2021.101371","article-title":"Venous thromboembolic (VTE) prophylaxis in Cushing disease patients undergoing transsphenoidal surgery","volume":"27","author":"McCormick","year":"2022","journal-title":"Interdiscip Neurosurg."},{"issue":"1","key":"2025081217164809500_lvaf139-B35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.thromres.2014.11.003","article-title":"Diabetes is associated with increased risk of venous thromboembolism: a systematic review and meta-analysis","volume":"135","author":"Bai","year":"2015","journal-title":"Thromb Res"},{"issue":"42","key":"2025081217164809500_lvaf139-B36","doi-asserted-by":"publisher","first-page":"e35329","DOI":"10.1097\/MD.0000000000035329","article-title":"Association between diabetes and venous thromboembolism: a systematic review and meta-analysis","volume":"102","author":"Ding","year":"2023","journal-title":"Medicine (Baltimore)."},{"key":"2025081217164809500_lvaf139-B37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejim.2015.10.001","article-title":"Is diabetes mellitus a risk factor for venous thromboembolism? A systematic review and meta-analysis of case-control and cohort studies","volume":"28","author":"Gariani","year":"2016","journal-title":"Eur J Intern Med"},{"issue":"1","key":"2025081217164809500_lvaf139-B38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The epidemiology of venous thromboembolism","volume":"41","author":"Heit","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2025081217164809500_lvaf139-B39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-16-0117","article-title":"Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study","volume":"175","author":"Dal","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2025081217164809500_lvaf139-B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.37029\/jcas.v1i1.13","article-title":"Is acromegaly a hypercoagulable condition? Case reports and review of the literature","volume":"1","author":"Al Dahmani","year":"2015","journal-title":"J Cancer Allied Spec"},{"issue":"3","key":"2025081217164809500_lvaf139-B41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s12020-008-9088-4","article-title":"Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI","volume":"33","author":"Erem","year":"2008","journal-title":"Endocrine"},{"issue":"1","key":"2025081217164809500_lvaf139-B42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1365-2265.1997.d01-1743.x","article-title":"Elevated fibrinogen levels decrease following treatment of acromegaly","volume":"46","author":"Landin-Wilhelmsen","year":"1997","journal-title":"Clin Endocrinol (Oxf)."}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf139\/63662102\/lvaf139.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/2\/270\/63662102\/lvaf139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/2\/270\/63662102\/lvaf139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T21:16:57Z","timestamp":1755033417000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/2\/270\/8185535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf139","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,3]]}}}